COLL Collegium Pharmaceutical Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: COLL

Price (delayed)

$32.75

Market cap

$1.06B

P/E Ratio

13.88

Dividend/share

N/A

EPS

$2.36

Enterprise value

$1.58B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 94

Collegium Pharmaceutical Inc. is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium's headquarters are located in Stoughton, Massachusetts.

Highlights
Collegium Pharmaceutical's EPS has soared by 74% YoY and by 19% from the previous quarter
The net income has soared by 71% YoY and by 19% from the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.collegiumpharma.com
Peers: UTHR LPCN SUPN

Key stats

What are the main financial stats of COLL

COLL stock price

How has the Collegium Pharmaceutical stock price performed over time
Intraday
5.44%
1 week
-1.86%
1 month
-5.29%
1 year
11.39%
YTD
-29.27%
QTD
-0.97%

Financial performance

How have Collegium Pharmaceutical's revenue and profit performed over time
Revenue
$796.33M
Gross profit
$483.18M
Operating income
$188.45M
Net income
$74.95M
Gross margin
60.7%
Net margin
9.4%
The net income has soared by 71% YoY and by 19% from the previous quarter
COLL's net margin is up by 42% year-on-year and by 16% since the previous quarter
Collegium Pharmaceutical's operating income has increased by 36% YoY and by 6% QoQ
Collegium Pharmaceutical's gross profit has increased by 26% YoY and by 4.3% QoQ

Price vs fundamentals

How does COLL's price correlate with its fundamentals

Growth

What is Collegium Pharmaceutical's growth rate over time

Valuation

What is Collegium Pharmaceutical stock price valuation
COLL P/E details
P/E
13.88
P/B
3.33
P/S
1.32
EV/EBIT
8.52
EV/EBITDA
8.36
EV/Sales
1.98
Collegium Pharmaceutical's EPS has soared by 74% YoY and by 19% from the previous quarter
COLL's P/E is 36% below its last 4 quarters average of 20.6
The equity is up by 33% year-on-year and by 3.6% since the previous quarter
The price to book (P/B) is 23% lower than the last 4 quarters average of 4.1 and 21% lower than the 5-year quarterly average of 4.0
COLL's price to sales (P/S) is 31% lower than its 5-year quarterly average of 1.8 and 17% lower than its last 4 quarters average of 1.5
The revenue is up by 20% year-on-year and by 2% since the previous quarter

Efficiency

How efficient is Collegium Pharmaceutical business performance
The company's return on assets has surged by 59% YoY and by 18% QoQ
The ROE is up by 39% YoY and by 11% QoQ
The ROIC has grown by 9% YoY and by 3.7% from the previous quarter
Collegium Pharmaceutical's ROS has increased by 8% YoY and by 4% from the previous quarter

Dividends

What is COLL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for COLL.

Financial health

How did Collegium Pharmaceutical financials performed over time
Collegium Pharmaceutical's total assets is 23% more than its total liabilities
The quick ratio has surged by 67% year-on-year and by 9% since the previous quarter
The current ratio has soared by 58% year-on-year and by 9% since the previous quarter
COLL's debt is 159% greater than its equity
The equity is up by 33% year-on-year and by 3.6% since the previous quarter
The debt to equity fell by 28% YoY and by 4.1% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.